A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer TRIFOUR study” - CAN04CLIN005

Cantargia AB0 个研究点目标入组 117 人开始时间: 2024年4月3日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Cantargia AB
入组人数: 117

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Signed informed consent form before conducting any specific procedure for the study., Patients testing positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must meet ALL the following criteria: a. Have CD4+ T-cell (CD4+) counts = 350 cells/µL; b. Have not had an opportunistic infection within the past 12 months. Patients on prophylactic antimicrobials can be included in the study; c. Should be on stable antiretroviral therapy for at least 4 weeks; d. Have an HIV viral load less than 400 copies/mL prior to enrolment., Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures., Negative serum pregnancy test within 7 days prior to enrolment for premenopausal women, and for women who have experienced menopause onset < 12 month prior to first dose of therapy. • For premenopausal women: agreement to remain abstinent or use single or combined non-hormonal contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 7 months after the last dose of study treatment. • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and to refrain from donating sperm during the same period, as defined below with female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of carboplatin/gemcitabine to avoid exposing the embryo., Female or male BC patients of = 18 years of age., Histologically confirmed TNBC that is either locally recurrent, inoperable and cannot be treated with curative intent or is metastatic: a. Documented Hormone Receptor (HR) negative BC based on local laboratory determination on the most recent tumor biopsy; b. Documented Human Epidermal Growth Factor Receptor 2 (HER2) negative BC based on local laboratory determination on the most recent tumor biopsy; c. Patients are eligible for the study irrespectively of BRCA1/2 mutational status., Patients should be eligible to receive gemcitabine and carboplatin as the following line of therapy. No more than 1 previous line of systemic therapy for the advanced disease is allowed., Documented progressive disease (i.e. biopsy sample, pathology or imaging report) from the last treatment., Eastern Cooperative Oncology Group (ECOG) Performance Status = 1., Patients must have at least one measurable lesion that can be accurately assessed at baseline and is suitable for repeated assessment by CT scan, MRI, plan X-ray or physical examination., Adequate organ and bone marrow function defined as follows: a. ANC = 1.500/mm3 (1.5x109/L), without previous G-CSF within 2 weeks prior to the study treatment; b. Platelets = 100.000/mm3 (100x109/L), without previous transfusion within 2 weeks prior to the study treatment; c. Hemoglobin = 9 g/dL (90 g/L), without previous transfusion within 28 days before starting with the study treatment; d. Serum creatinine = 1.5 x ULN or estimated creatinine clearance = 60 mL/min as calculated using the Cockcroft-Gault formula; e. Total serum bilirubin = 1.5 x ULN (= 3.0 x ULN if Gilbert´s disease); f. AST and/or ALT = 3.0 x ULN (= 5.0 x ULN if liver metastases present); g. Alkaline phosphatase = 2.5 x ULN (= 5.0 x ULN if bone or liver metastases present)., Resolution of all acute toxic effects of prior anti-cancer therap

排除标准

•Patient has received extended field radiotherapy = 4 weeks before the start of treatment (= 2 weeks for limited field radiation for palliation), and who has not recovered to = Grade 1, according to NCI CTCAE v5.0, from related AEs of such therapy (except for alopecia)., Pregnant or lactating or intending to become pregnant during or within 6 months after the last dose of study treatment., Known hypersensitivity or allergy to any component of the nadunolimab, carboplatin or gemcitabine drug formulations, and known hypersensitivity to platinum-containing compounds., Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications., Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before the first dose of study drug or 5 half-lives, whichever is shorter., Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina, known left ventricular ejection fraction (LVEF) < 50%., Presence of an abnormal ECG that is clinically significant in the investigator’s opinion., Patients with uncontrolled brain metastases., Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to enrolment., Severe (Grade 3) infection requiring oral or IV antibiotics within 4 weeks prior to enrolment., Positive hepatitis B surface antigen (HBsAg) test at screening. Total hepatitis B core antibody (HBcAb) test at screening must be negative., Positive hepatitis C virus (HCV) antibody test at screening: if positive, HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.

研究者

发起方

Cantargia AB

相似试验

进行中（未招募）

1 期

A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. TRIFOUR study”.nresectable locally advanced or metastatic triple negative breast cancer.MedDRA version: 23.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 100000004864

EUCTR2021-003402-46-ESCantargia AB116

进行中（未招募）

1 期

A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR geneChemotherapy naïve, EGFR mutant non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001687-30-ESEuropean Thoracic Oncology Platform (ETOP)95

进行中（未招募）

1 期

EUCTR2019-001687-30-DEETOP IBCSG Partners Foundation95

招募中

不适用

A ClinicalI trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistance

KCT0005588Yonsei University Health System, Severance Hospital30

进行中（未招募）

1 期

A Phase 2 trial using ARV-471 or Anastrozole in Post-Menopausal Women with Breast Cancer Prior to Surgery.Post-menopausal women with ER+ HER2– breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10083232Term: HER2 negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005081-17-DEArvinas Estrogen Receptor, Inc. (Arvinas)150